Global BCG Vaccine for Tuberculosis (TB) Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG Vaccine for Tuberculosis (TB) Market Insights, Forecast to 2034
BCG Vaccine for Tuberculosis (TB) provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB.
Global BCG Vaccine for Tuberculosis (TB) market is expected to reach to US$ 396.3 million in 2024, with a positive growth of %, compared with US$ 373.9 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, BCG Vaccine for Tuberculosis (TB) industry is evaluated to reach US$ 549.6 million in 2029. The CAGR will be 5.6% during 2024 to 2029.
The BCG (Bacillus Calmette-Guérin) vaccine for tuberculosis (TB) is driven by several key factors that influence the demand for this vaccine and its role in addressing the global TB burden
Tuberculosis PrevalenceTB remains a significant global health issue, especially in regions with high prevalence rates. The BCG vaccine is used as a preventive measure in areas with a high burden of TB cases.
TB Control and Eradication EffortsThe BCG vaccine is a critical tool in the fight against TB, supporting efforts to control the spread of the disease and eventually work towards its eradication.
Childhood Immunization ProgramsMany countries include the BCG vaccine as a part of their childhood immunization schedules to protect infants and children against TB.
Protection Against Severe FormsThe BCG vaccine is particularly effective in protecting children against severe forms of TB, such as TB meningitis and disseminated TB.
Healthcare Worker ProtectionHealthcare workers, especially those in regions with a high TB burden, may receive the BCG vaccine to reduce their risk of TB infection.
Reducing TB-Related MortalityThe BCG vaccine contributes to reducing TB-related mortality, especially in high-risk populations such as infants and individuals with compromised immune systems.
Drug-Resistant TB PreventionIn regions with drug-resistant TB strains, the BCG vaccine can help prevent the development of severe forms of TB and reduce the risk of transmission.
Global Health InitiativesOrganizations such as the World Health Organization (WHO) promote the use of the BCG vaccine as part of global TB control strategies.
High-Risk PopulationsThe BCG vaccine is often recommended for individuals at higher risk of TB exposure, such as those living in crowded or high-risk areas.
Public Health AwarenessPublic health campaigns and awareness efforts promote the importance of TB prevention through vaccination, driving demand for the BCG vaccine.
TB Elimination GoalsMany countries have set goals to eliminate TB as a public health threat. The BCG vaccine plays a role in achieving these goals.
Immunity BuildingThe BCG vaccine is known to enhance the immune response, potentially offering some level of protection against other respiratory infections.
Global Travel and MigrationTB transmission can occur through global travel and migration. The BCG vaccine may be recommended for individuals traveling to or from regions with high TB prevalence.
Research and DevelopmentOngoing research aims to improve the effectiveness and administration of the BCG vaccine, which could increase its adoption and impact.
Integration into Routine Immunization ProgramsThe integration of the BCG vaccine into routine immunization programs helps ensure that a larger portion of the population receives the vaccine.
Collaboration and FundingPartnerships between governments, international organizations, and healthcare institutions drive the availability and accessibility of the BCG vaccine.
Pandemic PreparednessThe ongoing COVID-19 pandemic has highlighted the importance of vaccine-preventable diseases, potentially increasing interest in vaccine research and development, including the BCG vaccine.
Report Covers
This report presents an overview of global BCG Vaccine for Tuberculosis (TB) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global BCG Vaccine for Tuberculosis (TB) market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC
Segment by Type
Immune Type
Therapy Type
Hospitals
Clinics
Others
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ BCG Vaccine for Tuberculosis (TB) plant distribution, commercial date of BCG Vaccine for Tuberculosis (TB), product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, BCG Vaccine for Tuberculosis (TB) introduction, etc. BCG Vaccine for Tuberculosis (TB) Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of BCG Vaccine for Tuberculosis (TB)
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global BCG Vaccine for Tuberculosis (TB) market is expected to reach to US$ 396.3 million in 2024, with a positive growth of %, compared with US$ 373.9 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, BCG Vaccine for Tuberculosis (TB) industry is evaluated to reach US$ 549.6 million in 2029. The CAGR will be 5.6% during 2024 to 2029.
The BCG (Bacillus Calmette-Guérin) vaccine for tuberculosis (TB) is driven by several key factors that influence the demand for this vaccine and its role in addressing the global TB burden
Tuberculosis PrevalenceTB remains a significant global health issue, especially in regions with high prevalence rates. The BCG vaccine is used as a preventive measure in areas with a high burden of TB cases.
TB Control and Eradication EffortsThe BCG vaccine is a critical tool in the fight against TB, supporting efforts to control the spread of the disease and eventually work towards its eradication.
Childhood Immunization ProgramsMany countries include the BCG vaccine as a part of their childhood immunization schedules to protect infants and children against TB.
Protection Against Severe FormsThe BCG vaccine is particularly effective in protecting children against severe forms of TB, such as TB meningitis and disseminated TB.
Healthcare Worker ProtectionHealthcare workers, especially those in regions with a high TB burden, may receive the BCG vaccine to reduce their risk of TB infection.
Reducing TB-Related MortalityThe BCG vaccine contributes to reducing TB-related mortality, especially in high-risk populations such as infants and individuals with compromised immune systems.
Drug-Resistant TB PreventionIn regions with drug-resistant TB strains, the BCG vaccine can help prevent the development of severe forms of TB and reduce the risk of transmission.
Global Health InitiativesOrganizations such as the World Health Organization (WHO) promote the use of the BCG vaccine as part of global TB control strategies.
High-Risk PopulationsThe BCG vaccine is often recommended for individuals at higher risk of TB exposure, such as those living in crowded or high-risk areas.
Public Health AwarenessPublic health campaigns and awareness efforts promote the importance of TB prevention through vaccination, driving demand for the BCG vaccine.
TB Elimination GoalsMany countries have set goals to eliminate TB as a public health threat. The BCG vaccine plays a role in achieving these goals.
Immunity BuildingThe BCG vaccine is known to enhance the immune response, potentially offering some level of protection against other respiratory infections.
Global Travel and MigrationTB transmission can occur through global travel and migration. The BCG vaccine may be recommended for individuals traveling to or from regions with high TB prevalence.
Research and DevelopmentOngoing research aims to improve the effectiveness and administration of the BCG vaccine, which could increase its adoption and impact.
Integration into Routine Immunization ProgramsThe integration of the BCG vaccine into routine immunization programs helps ensure that a larger portion of the population receives the vaccine.
Collaboration and FundingPartnerships between governments, international organizations, and healthcare institutions drive the availability and accessibility of the BCG vaccine.
Pandemic PreparednessThe ongoing COVID-19 pandemic has highlighted the importance of vaccine-preventable diseases, potentially increasing interest in vaccine research and development, including the BCG vaccine.
Report Covers
This report presents an overview of global BCG Vaccine for Tuberculosis (TB) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global BCG Vaccine for Tuberculosis (TB) market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
AJ Vaccines
Serum Institute of India
Intervax
GSBPL
Statens Serum Institute
Biomed Lublin
ANLIS Malbran
Fundação Ataulpho de Paiva
BB-NCIPD
Taj Pharmaceuticals
Bio Farma
Microgen
Torlakinstitut
Institut Pasteur de Tunis
IVAC
Segment by Type
Immune Type
Therapy Type
Segment by Application
Hospitals
Clinics
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ BCG Vaccine for Tuberculosis (TB) plant distribution, commercial date of BCG Vaccine for Tuberculosis (TB), product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, BCG Vaccine for Tuberculosis (TB) introduction, etc. BCG Vaccine for Tuberculosis (TB) Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of BCG Vaccine for Tuberculosis (TB)
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices